Background-Despite recent discoveries of new genetic risk factors, the majority of risk for coronary artery disease (CAD) remains elusive. As the most proximal sensor of DNA variation, RNA abundance can help identify subpopulations of genetic variants active in and across tissues mediating CAD risk through gene expression.
G enomic data sets are changing how scientists approach research of common complex diseases, such as coronary artery disease (CAD). 1 Up to 153 common single-nucleotide polymorphisms (SNPs) associated (P<10 -5 ) with CAD and myocardial infarction (MI) have been identified in genomewide association (GWA) studies. 2, 3 Forty-six of these SNPs were found genome-wide significant (P=5×10 −8 ) also in metaanalyses of GWA studies. 2, 4, 5 An important task is to reveal the biological mechanisms by which these SNPs exert risk for CAD and MI. An even larger task is to discover additional CAD risk variants because those found to date explain only ≈10% of the inherited risk variation in the population, whereas the remaining ≈90% of CAD risk heritability reside remains elusive.
Some of the missing heritability will be explained by rare disease variants and epigenetic inheritance (possibly not mediated by DNA). Another possibility is that parts of the missing heritability are explained by many disease-associated DNA variants acting together in and across tissues through common biological processes, networks, or individual pathways. 6 In traditional analysis of GWA data sets, where DNA variants are considered one by one, such variants may not reach genomewide significance (<10 -5 ) and are therefore typically ignored. However, if several of these subsignificant variants (P=10 -2 to 10 -5 ) are considered together, they may constitute a substantial contribution to CAD heritability. 1, 7 Disease-associated DNA variants may modify CAD risk directly by acting on the arterial wall during coronary artery lesion formation (primarily involving leukocytes and endothelial and smooth muscle cells). However, because CAD is a systemic disease, risk loci may modify risk indirectly in metabolic tissues. 8 As the most proximal sensor of DNA variation, RNA abundance at any stage of disease reflects interactions between the genotype and the microenvironment within one or several tissues. Accordingly, the risk contributions of expression quantitative trait loci (eQTLs) proximal to disease phenotypes can be identified through parallel assessments of allelic distributions of SNPs, tissue expression profiles across disease-relevant tissues, and GWA data sets. 1, 9 In this study, we generated new genotype and global gene expression data on DNA and RNA samples from CAD patients in the Stockholm Atherosclerosis Gene Expression (STAGE) study 10 to identify eQTLs in and across 7 tissues. To evaluate the importance of different subsets of the eQTLs as carriers of CAD risk, we primarily used 2 independent GWA data sets of CAD, one from the Myocardial Infarction Genetics Consortium (MIGen) 11 and one from the Wellcome Trust Case Control Cohort (WTCCC). 12 
Methods The STAGE Study
In the STAGE study, 7 vascular and metabolic tissues of wellcharacterized CAD patients were sampled during coronary artery bypass grafting as described. 10 The Ethical committee of the Karolinska Hospital approved the study, and patients gave written consent (Dnr 004-02). Patients were included if they were eligible for coronary artery bypass grafting and had no other severe systemic diseases (eg, widespread cancer and active systemic inflammatory disease).
Genotyping and Global Gene Expression Analyses in the STAGE Study
STAGE tissue samples were obtained from atherosclerotic arterial wall (AAW), internal mammary artery (IMA), liver, skeletal muscle (SM), subcutaneous fat (SF), and visceral fat (VF) 10 and stored at -80°C in RNAlater (Ambion). Preoperatively, patients were examined and fasting whole blood (WB) was obtained for DNA and RNA isolations and biochemistry. DNA and RNA were isolated with Qiagen Mini/Midi-Kits (Ambion). DNA from 109 patients ( Table 1) with sufficient quantities and qualities (≥1 μg, 1.7>260/280>1.9 with Nanodrop, Agilent) was genotyped with GenomeWideSNP_6 arrays (Affymetrix). Allele frequencies for 909 622 SNPs were determined with the Birdseed algorithm in Affymetrix Power Tools (v 1.14.2); 530 222 autosomal SNPs with call rates of 100% and minor allele frequency >5% and in Hardy-Weinberg equilibrium (P>10 -6 ; quality controlled [QC] SNP set) were used for downstream analysis. Custom-made HuRSTA-2a520709 arrays (Affymetrix) were used for gene expression profiling of total RNA samples (≥5 μg, 1.95>260/280>2.05 with Nanodrop, Agilent) from the 109 genotyped patients (AAW, n=68; IMA, n=79; liver, n=77; SM, n=78; SF, n=63; VF, n=88, and WB, n=102). Robust multiarray average was used for background subtraction, normalization, and summarizing of raw microarray data (Affymetrix Power Tools, v 1.14.2). A custom-made chip description file was used to match 381 707 probes on the array to 19 610 probe sets for unique genes (to avoid cross-hybridization between alternative transcripts) according to the hg19 human genome assembly.
eSNP Discovery
Each expression trait (probe set signal) was tested for association with the allele frequency of each genotyped SNP using the Kruskal-Wallis test and false-discovery rates (FDRs) to control family-wise error rates. 13 First, an empirical null distribution was estimated for each tissue by calculating association P values between SNPs and expression traits in data sets with randomized sample labels (patient identification numbers). Next, the FDR at level α was controlled by determining the P value threshold P α such that the ratio of the average number of associations with P value <P α under the null distribution to the number of associations with P value <P α in the real data was equal to α. We found that the empirical null distribution was stable and 3 permutation runs per tissue were sufficient for convergence, indicating the distributions among the expression traits were largely exchangeable. At an FDR of 15%, the nominal genome-wide P-value thresholds for the Kruskal-Wallis test were 2.9×10 −7 (AAW), 2.9×10 −7 (IMA), 6.0×10 −7 (liver), 3.5×10 −7 (SM), 4.0×10 −7 (SF), 2.3×10 −7 (VF), and 6.0×10 −7 (WB). Cis-acting expression single-nucleotide polymorphisms (eSNPs) were defined as SNPs within 1 Mb of the transcription start or end sites of the affected gene. All other eSNPs were defined as trans-acting. Because multiple testing corrections considering all SNPs (≈10 10 pairwise tests) are too conservative for identifying cis-eSNPs (≈7×10 6 pairwise tests), the above procedure was repeated, this time testing only SNPs within 1 Mb of the transcription Cis-and trans-acting eSNPs identified in 7 different tissues and their corresponding number of genes and P value cutoff. AAW indicates atherosclerotic arterial wall; eSNP, expression single-nucleotide polymorphism; IMA, internal mammary artery; NA, not applicable; SF, subcutaneous fat; SM, skeletal muscle; VF, visceral abdominal fat; and WB, whole blood. start or end site for each gene. At the threshold of FDR=15%, nominal P-value thresholds for the Kruskal-Wallis test for cis-acting eSNPs were 2.5×10 -4 (AAW), 2.9×10 -4 (IMA), 5.5×10 -4 (liver), 3.0×10 -4 (SM), 3.0×10 -4 (SF), 2.4×10 -4 (VF), and 6.7×10 -4 (WB). This resulted in a total of 29 530 cis-eSNPs for 6450 genes, corresponding to 8156 eQTLs (the eSNP most strongly associated with each gene), and 1494 trans-acting eSNPs for 1222 genes (Table 1 ; Methods in the Data Supplement). Of 29 530 cis-eSNPs, 15 012 eSNPs were identified in WB, which, at least in part, likely is attributed to the relatively larger sample number of this tissue (n=102). However, on the whole, variation in STAGE sample sizes (n=63-88 besides WB) seemed to have subtle, if any, effect on the number of identified eSNPs. For regional plots, LocusZoom 14 was used for selected CAD/MI risk loci, plotting for each SNP in the QC set its lowest association P value over all genes in all tissues and using the Europe population, hg19 genome assembly, and 1000 Genomes 15 to calculate linkage disequilibrium (LD).
Clustering Based on Tissue mRNA Profiles and eSNP Sets
We analyzed 555 mRNA profiles (considered as 19 610-dimensional vectors) by multidimensional scaling using the Euclidean distance and Sammon's nonlinear mapping criterion. Tissues were also clustered according to eSNP overlap by constructing a phylogenetic tree from 29 530-dimensional vectors recording the presence/absence of an eSNP in a tissue, using the neighbor-joining method with average linkage and the Jaccard distance measure.
Genic Regulatory and Evolutionary Genomic Features
Enrichments of eSNPs at genomic regions with certain features were compared to the bulk (n=963) of verified risk loci 16 identified in GWA studies 3 and present in our QC SNP set, using chromosome-bound circular permutations. 17 The null hypothesis of the permutation method is that eSNPs and non-eSNPs are equally likely to be located (ie, found) within each genomic annotation. The real data were compared against 20 000 permuted genomes generated from the QC SNP set, which preserved the internal structure of the genome in terms of relative distance between SNPs and the observed clustering of genomic features while analyzing the LD structure (LD partners, r 2 >0.9) around all SNPs (Methods in the Data Supplement). 17 The permuted genomes were used to calculate the odds ratios of risk enrichment/depletion of the real data in genic and regulatory regions, evolutionarily conserved regions, and regions with distinctly different histone modification patterns ( Table I in the Data Supplement). Human umbilical vein endothelial cells were the most CAD-relevant cell type for which histone modification data were available.
CAD/MI Risk Enrichment
To examine eQTLs and tissue-defined subsets thereof for relative enrichment in CAD/MI risk, 18, 19 we used the MIGen 11 and WTCCC 12 GWA data sets. The queried eQTL set (real set >10 eQTLs; Table  II in the Data Supplement) was matched against SNPs of the GWA data set and expanded with 1000 Genomes 15 to include SNPs in that data set in strong LD (r 2 >0.8) with eQTLs. The expanded set was compared with 10 000 SNP sets of equal size randomly sampled from each GWA data set with matching chromosomal distribution. The fold enrichment was computed from the percentage of diseaseassociated SNPs (P<0.05) in the expanded set compared with the average percentage of disease-associated SNPs in the random sets. The enrichment P value was determined from the percentage of random sets with the same fold enrichment as the real set (or higher; Methods in the Data Supplement).
eQTL-Associated Gene Sets
For highly risk-enriched sets of eQTLs, many associated gene sets was identified. Such gene set was identified by first seeking genes associated in cis or in trans with each of the eQTLs of interest across the 7 tissues at a nominal P value for the Kruskal-Wallis test (P<1×10 -3 ). Next, highly coexpressed genes active in the same tissue as eQTL-gene pair was identified forming the final gene set (Pearson correlation coefficient, >0.85). The threshold parameters were those yielding optimal gene set sizes from all combinations of association P-value thresholds of 5×10 -4 , 1×10 -3 , and 5×10 -3 and Pearson correlation threshold of 0.8, 0.85, and 0.9. eQTLs and associated gene sets in a tissue were assessed for molecular functions in Gene Ontology categories. 20 Functional-enrichment P values were determined with Fisher exact test and Benjamini and Hochberg FDR corrections for multiple testing.
Small Interfering RNA Perturbation of THP-1 Macrophages Incubated With Acetylated Low-Density Lipoproteins
As previously described, 21 THP-1 monocytic cells were differentiated into macrophages using phorbol myristate acetate and thereafter transfected with small interfering RNA targeting each master regulator (one at a time) or mock-transfected ( Table III in the Data Supplement). Next, the cells were incubated with acetylated low-density lipoproteins (50 μg/mL) for 48 hours allowing foam cells to form. The cholesterolester accumulation in the foam cells were determined by measuring and subtracting free cholesterol from total cholesterol adjusted for protein concentration (Methods in the Data Supplement).
Results

The STAGE Study and Tissue Gene Expression Patterns
The STAGE cohort consisted of typical CAD cases with well-managed hyperlipidemia and hypertension (>90% on β-blocker and plasma-lipid-lowering regimens); 20% had diabetes mellitus (Table IV in the Data Supplement). The expression patterns of the 19 610 genes across 7 tissues in the STAGE study segregated the tissues into well-defined groups, reflecting unique tissue functions ( Figure 1A ). Gene expression patterns in AAW and nonatherosclerotic IMA were closely related but, importantly, well segregated; gene expression patterns in SF and VF were more intermixed ( Figure 1A ; Figures I and II in the Data Supplement).
Most Cis-Acting eSNPs Affect Gene Expression Only in One Tissue
The allelic distributions of 29 530 SNPs within 1 Mb of the transcription start site (TSS) were associated with mRNA levels of 6450 unique genes (cis-eSNPs [eSNPs]; FDR 15%; Methods in the Data Supplement; Table 1 ; and Figure III in the Data Supplement). Of the identified 29 530 eSNPs, 22 101 were identified in only one tissue (tissue-specific eSNPs) and 7429 in ≥2 tissues (multitissue eSNPs). Similar proportions of tissue-specific versus shared eSNPs have been reported. [22] [23] [24] [25] Also identified were 1494 trans-eSNPs (>1 Mb from the TSS), mainly in WB (38%). Within these sets, we identified 39 eSNPs matching SNPs previously associated with CAD/ MI risk in GWA studies, 4 whereof 21 exact matches and 18 in strong LD (r 2 >0.8; Table V and Figure IV in the Data Supplement). On average, the multitissue eSNPs were closer to the TSS than the tissue-specific eSNPs ( Figure 1D and 1E) , as reported. 22, 26 Whether the multitissue eSNPs were present in 2 or more tissues did not affect their positions relative to the TSS ( Figure 1D ). The notion that eSNPs more distal to the TSS have tissue-specific effects on gene expression is consistent with the fact that tissue-specific enhancer regions are commonly more distal to the TSS. Similarly, the notion that eSNPs close to the TSS have tissue-independent effects on gene expression (across 2 or more tissues) is consistent with the idea that the TSS of a gene is similar across tissues.
Shared eSNPs in Arterial Wall and Fat Deposits
eSNPs in arterial wall samples (AAW, IMA) and fat deposits (VF and SF) formed a common cluster, as did those in liver and WB; eSNPs in SM formed an isolated cluster ( Figure 1B) . In fact, ≤60% of the eSNPs in AAW, IMA, VF, and SF were shared ( Figure 1C ). Thus, in CAD, diseased and healthy arteries seem to share most regulatory SNPs with fat depots, fewer with liver and WB, and fewest with SM. Venn diagrams for eQTLs in all combinations of 4 tissues are shown in Figure V in the Data Supplement.
Multitissue eQTLs Carry More Inherited CAD Risk Than Tissue-Specific eQTLs
The strongest eSNP association of a gene is referred to as its eQTL. To assess the importance of different sets of tissuespecific and multitissue eQTLs for inherited risk of CAD/ MI, we used the MIGen 11 and WTCCC 12 GWA data sets to analyze risk enrichment ( Table II in CAD is a complex disease that is particularly dependent on the molecular status of the metabolic tissues that drive atherosclerosis and thrombosis in the vascular bed. Thus, eQTLs present only in one tissue (tissue-specific) may have different roles from multitissue eQTLs, affecting gene expression across several tissues in mediating CAD risk. We examined this possibility by assessing risk enrichments of different sets of eQTLs present in single or multiple tissues (>2 tissues). According to MIGen GWA data set, only tissue-specific eQTLs in SM, SF, and WB carried CAD/MI risk (Figure 2A , red bars). However, for multitissue eQTLs, all tissues but SM and VF were risk enriched ( Figure 2B, red bars) . According to the WTCCC, the risk-enrichment levels for both tissuespecific and multitissue eQTLs were higher, but multitissue eQTLs were again found to be more risk enriched than tissuespecific eQTLs (Figure 2A and 2B, blue bars). 
As eQTLs Are Shared Across More Tissues They Are Increasingly Risk Enriched
Because multitissue eQTLs (>2 tissues) were more risk enriched than tissue-specific eQTLs, we asked whether the CAD/MI risk of eQTLs increases with the number of tissues in which these eQTLs affect gene expression (from 2 to 7 tissues). Indeed, this proved to be the case: risk enrichment peaked in combinations of 4 to 6 tissues (1.2-fold, P<8.0×10 −4 ) according to the MIGen data set and in combinations of 6 tissues (2.7-fold, P<2.0×10 −86 ) according to the WTCCC data set ( Figure 2C ). Thus, eQTLs that affect gene expression across 4 to 6 tissues seem to be the most relevant as carriers of CAD risk.
When we instead only considered the highest enrichment for a combination of specific tissues (from 2 to 7), the riskenrichment scores according to both GWA data sets generally increased from tissue-specific eQTLs ( Figure 2D , outer circle, ≤1.2-fold, P<4.0×10 −9 ) to those active in combinations of 5 or more tissues ( Figure 2D , inner circle, ≤8.5-fold, P<1.7×10 −43 ).
Multitissue eQTLs Are Well Conserved and Enriched at Sites of Regulatory Elements
Most verified GWA hits are enriched at sites of regulatory elements, 17, 27 suggesting that disease-risk loci affect disease by modifying regulatory hot spots rather than by modifying Figure 2 . Inherited risk enrichment for Stockholm Atherosclerosis Gene Expression (STAGE) expression quantitative trait loci (eQTLs) according to 2 major genome-wide association (GWA) studies of coronary artery disease (CAD)/myocardial infarction (MI). Inherited CAD/MI risk enrichments of STAGE eQTLs and subsets thereof were sought as described 19 using 2 independent GWA studies: Myocardial Infarction Genetics Consortium (MIGen) 11 (red bars) and Wellcome Trust Case Control Cohort (WTCCC) 12 (blue bars). Sets of eQTLs were tested for enrichment against 10 000 random sets at a linkage disequilibrium of r 2 >0.8 (see Methods in the Data Supplement). Bars indicate enrichment results that are statistically significant (P<10 −3 ). A, CAD/MI risk enrichments for tissue-specific eQTLs divided by tissues. B, CAD/MI risk enrichments for multitissue eQTLs divided by tissues. C, CAD/MI risk enrichments of eQTLs shared in all combinations of 2 to 7 tissues. D, Pie chart showing risk enrichments for eQTLs in specific tissues (outer circle, 1 pie=1 tissue) and the risk enrichments of multitissue eQTLs active in one given and a combination of 1 to 4 tissues (toward the center). Colors indicate degree of enrichment. For multitissue eQTLs, the highest enrichment for each tissue combination is indicated. AAW indicates atherosclerotic arterial wall; IMA, internal mammary artery; SF, subcutaneous fat; SM, skeletal muscle; VF, visceral fat; and WB, whole blood. the expression of specific genes. Conceivably, eQTLs are enriched at regulatory sites. To investigate this possibility, we compared the regulatory element enrichment patterns of all the identified eSNPs (n=29 530) and the tissue-specific (n=22 101) and multitissue (n=7429) eSNPs with the regulatory element enrichment patterns of 963 established GWA loci 16 (GWA-SNPs) in a range of regulatory element subcategories ( Table I in the Data Supplement). Strikingly and as opposed to tissue-specific eSNPs ( Figure VI in the Data Supplement), the regulatory element enrichment patterns for the multitissue eSNPs were significantly enriched, and more so than those for GWA-SNPs, regardless of the subcategory (genic and regulatory regions, evolutionary and conserved regions, or regions of histone modification in human umbilical vein endothelial cells; Figure 3A-3C ). This finding strongly suggests that in contrast to tissue-specific eQTLs, and to a greater extent than GWA-SNPs, multitissue eSNPs/eQTLs affect gene expression across tissues mainly by modifying DNA regulatory elements at well-conserved genomic sites. This finding is consistent with their tissueindependent effects on gene expression (ie, being multitissue eQTLs) and possibly with their greater importance as carriers of CAD risk.
Forty-Two Multitissue eQTLs Found to Be Important Carriers of CAD/MI Risk
The finding that eQTLs shared across combinations of tissues (>4) were more enriched with inherited CAD/MI risk than tissue-specific eQTLs and those shared across fewer tissues (<4) suggests that there might be specific subsets of highly shared eQTLs that are particular important carriers of CAD risk. We therefore examined eQTLs active across specific combinations of the 7 tissues. Twelve eQTLs in one combination of 5 tissues (AAW, liver SF, VF, and WB) and 30 eQTLs in a combination of 6 tissues (IMA, liver, SM, SF, VF, and WB) were found highly enriched in CAD/MI risk according to the MIGen (8.5-fold, P=1.6×10 −43 ) and WTCCC (3.6-fold, P=2.2×10 −30 ) GWA data sets (Tables  VI and VII in the Data Supplement) . Combined, these 42 eQTLs were found to be risk enriched by ≤7.3-fold (7.3fold, P=7.7×10 −20 in WTCCC and 2.3-fold, P=3.1×10 −6 in MIGen). To validate the 42 eQTLs in a broader set of GWA studies of CAD, we interrogated the GWA meta-analysis of CAD undertaken by the Coronary Artery Disease Genome Wide Replication And Meta-analysis (CARDIoGRAM) consortium. 4 The CARDIoGRAM data set consists of ≈22 000 CAD cases and ≈60 000 controls and includes the WTCCC and MIGen data sets, which contribute 14% of the cases and 7% of the controls. 4 Using this GWA data set, we found that the 42 eQTLs were risk enriched by 4.2-fold (P<1.1×10 −54 ). The CAD associations for the individual SNPs in this set are shown in Table VIII in the Data Supplement.
Gene Sets Downstream of Multitissue eQTLs
To assess downstream effects on gene expression governed by the multitissue eQTLs, we first identified genes associated in cis or in trans with each of the 42 eQTLs ( Figure VII in the Data Supplement; P<10 -3 by Kruskal-Wallis test) and then identified highly coexpressed genes downstream of the master regulators (absolute Pearson correlation coefficient, >0.85). In this fashion, 29 gene sets (with ≥30 genes in gene set in different tissues) for 16 of the 42 eQTLs, termed as master regulator eQTLs, involving 19 cis-regulated genes, termed as master regulator genes, were identified. According to the CARDIo-GRAM GWA data set, these 16 eQTLs were further enriched with CAD risk (8.4-fold, P=5.5×10 -51 ). To put the fold enrichment of risk in perspective, we tested the risk enrichment for the 153 CAD risk SNPs established by GWAS 2 and found it to be 10-fold (P<10 -99 ) according to the CARDIoGRAM GWA data set.
To further evaluate the role of these 16 master regulatory eQTLs, we first used Gene Ontology 20 to assess the functional characteristics of the 29 gene sets. Nineteen gene sets returned significant functional enrichments that without exception revealed biological processes relevant to CAD: T-cell differentiation, regulation of cholesterol efflux, oxidation-reduction process, steroid metabolic process, blood vessel development, respiratory electron transport chain, and cell cycle ( Table 2; Tables VI, VII, and IX in the Data  Supplement) .
We also examined whether clustering patients according to expression levels within each of the 29 gene sets would result in patient subgroups associated with CAD traits or clinical phenotypes. Remarkably, as many as 27 of the 29 gene sets clustered the STAGE patients according to ≥1 CAD trait or clinical phenotype (Table 2 ; Table IX in the Data Supplement). Heat maps of patient clusters within each of the 29 gene sets are shown in Figure VII in the Data Supplement.
Master Regulatory eQTL Genes
In view of the master regulatory role of the 16 eQTLs in CAD, it is interesting to know more about their cis-regulated genes (master regulators). Three of the 4 master regulators with gene sets found to be associated with the primary CAD trait-the extent of coronary atherosclerosis assessed from preoperative angiograms in the STAGE patients (CAD score in Table 2 )-were identified in abdominal fat (VF): G3BP1, PSORSIC3, and FLYWCH1. The gene sets of G3BP1 (a DNAunwinding enzyme) and PSORSIC3 (a psoriasis-susceptibility gene) were highly enriched in cell-cycle genes (P<1×10 −21 and P<1×10 −48 ). The gene set of FLYWCH1 (a zinc finger-containing protein) was instead enriched in oxidation-reduction processes (P<1×10 −11 ).
A blood (WB) gene set (n=53) with the master regulator SNAPIN (SNAP-associated protein) was also found to be Table 2 ). This SNAPIN gene set was also associated with inherited diabetes mellitus, years of smoking, and physical activity in STAGE patients ( Table 2 ; Table IX in the Data Supplement). Another SNAPIN gene set, identified in abdominal fat (VF), was found associated with low-density lipoprotein cholesterol levels ( Table 2) . For yet 2 other SNAPIN-associated gene sets (both identified in the arterial wall [IMA]) that were highly enriched in steroid metabolic processes (P<1×10 −20 ), one set was found associated with C-reactive protein levels of the STAGE patients and the other with the diagnosis of allergy ( Table 2) . Master regulator eQTL genes related to other phenotypes of the STAGE patients, including plasma levels of lipids, glucose, and C-reactive protein, are presented in Table IX in the Data Supplement.
Master Regulators Associated With Extent of Coronary Atherosclerosis Validated by Small Interfering RNA in Foam Cells
The master regulatory genes G3BP1, PSORSIC3, FLYWCH1 (in VF), and SNAPIN (in WB) were all associated with CAD score in STAGE patients, suggesting these genes are important regulators of the formation of atherosclerosis. A key event of atherosclerosis is the formation of foam cells. To validate these genes, we examined the effect of small interfering RNA targeting of G3BP1, PSORSIC3, FLYWCH1, and SNAPIN on cholesterol-ester accumulation in THP1-foam cells. Besides SNAPIN, small interfering RNA targeting of G3BP1, PSORSIC3, and FLYWCH1 had pronounced effects on cholesterol-ester accumulation in THP-foam cells ( Table 3 ; Table III in the Data Supplement).
Discussion
In this study, we identified eQTLs from 7 CAD-relevant tissues from the same patients and used well-established GWA data sets to assess their importance for inherited risk of CAD. Our analysis confirmed that SNPs regulating gene expression (ie, eSNPs/eQTLs) are more likely to carry disease risk than nonregulatory SNPs. 18, [22] [23] [24] [25] Importantly, we also found that eQTLs affecting gene expression across multiple tissues carried substantially more inherited CAD risk than eQTLs affecting gene expression in isolated tissues. Unlike tissue-specific eQTLs, these multitissue eQTLs affected gene expression largely by modifying well-conserved regulatory elements of the genome rather than by modifying the expression of specific genes. In fact, the overall CAD-risk enrichment of multitissue eQTLs at these regulatory sites was significantly greater than that of GWA hits reported by the Encyclopedia of DNA Elements (ENCODE) Consortium and others. 17 Thus, multitissue eQTLs are relatively well conserved and important in modulating pathophysiological responses to gene expression.
We also identified 42 multitissue eQTLs highly enriched with inherited CAD/MI risk, as shown by our analysis of 2 isolated GWA data sets and the combined data set of GWA studies of CAD from the CARDIoGRAM Consortium. 4 Sixteen of these 42 eQTLs were further enriched with inherited risk and linked to 19 master regulatory genes with 29 downstream gene sets in specific tissues. Analysis of the functional and clinical associations of these gene sets further validated the roles of the 16 multitissue eQTLs and their 19 regulatory genes in CAD. Specifically, 19 of 29 gene sets were enriched with biological processes highly relevant to CAD, and 27 sets clustered STAGE patients by several key CAD traits and clinical phenotypes, including 4 master regulatory genes linked to the extent of coronary atherosclerosis; 3 of these genes also affected the extent of foam cell formation in vitro. By analyzing 7 tissues from the same patients, we identified 2 sets of eQTLs affecting gene expression in combinations of 5 and 6 tissues that were highly enriched in CAD/ MI risk (≤8.5-fold, P=1.6×10 −43 ). Previous studies of the risk enrichment of eQTLs have examined at most 4 tissues, often fewer. 18, 19, [22] [23] [24] [25] The marked risk enrichment of eQTLs affecting gene expression across >4 tissues was unexpected and may reflect the complexity of CAD. Although atherosclerosis (the key process in CAD) occurs in the arterial wall, its progression and composition (which determine clinical outcomes) are also determined by blood constituents (eg, plasma cholesterol and glucose) that in turn are dependent on the molecular status in several organs particularly those involved in metabolism. Hence, eQTLs affecting specific genes in isolated tissues may indeed be less important for the development and clinical outcome of CAD than eQTLs affecting high hierarchical regulatory elements that influence gene expression across multiple vascular and metabolic tissues.
Sixteen of 42 multitissue eQTLs were linked to 19 genes with master regulatory roles in CAD (Tables 2 and  3 ). Unexpectedly, the downstream effects of these master regulatory eQTLs were tissue-specific and seemingly dependent on contexts in some but not all of the tissues in which the eQTLs were active. Such contexts appeared largely present in VF, which contained many gene sets, but were also in the arterial wall (AAW and IMA) and blood (WB), where most of the gene sets were identified (Tables 2 and 3) .
Besides the 4 master regulatory genes associated with CAD ( Table 2 , G3BP1, FLYWCH1, PSORS1C3, and SNAPIN), we identified additional 15 that were associated with other CAD phenotypes (eg, plasma levels of low-density lipoprotein; Table IX in the Data Supplement). Of 19 master regulators in total, 13 (ABHD16A, SNAPIN, S100A1, S100A13, PRRC2A, PHOSPHO2, PBXIP1, HSPC157, GPANK1, G3BP1, FLYWCH1, CKAP2, and C15orf57) had not previously been associated with CAD or any of its subphenotypes, as judged from the Genetic Association Database. 28 S100A1, however, has been associated with breast cancer. The remaining 6 master regulators had been associated with CAD-related subphenotypes: diabetes mellitus type 2 (SIGLEC12, VARS, and HLA-C), left ventricular failure (PSORS1C3), plasma triglycerides (PSORS1C3), rheumatic heart disease (HLA-C), coronary aneurysm (HLA-C), heart rate (LGALS4), and blood pressure and arterial hypertension (CTNS; Table X in the Data Supplement). Interestingly, genetic variation in SIGLEC12 (a master regulator associated with hypertension in the STAGE patients; Table IX in the Data Supplement) and treatment of hypertension have been linked to cardiovascular outcomes. 29 Although our finding that multitissue eQTLs carry more inherited risk than tissue-specific eQTLs may well be explained by complex interactions between metabolic and vascular tissue in CAD development, we considered other explanations for this observation. For example, could increasingly shared (ie, multitissue) eQTLs be more strongly associated with their expression traits (have higher eQTL P values than tissue-specific eQTLs) and thus be a more robust subpopulation of eQTLs that therefore are more likely to be risk-enriched? This was not found to be the case: first, there was no correlation between the strength of association between SNPs and their expression traits (ie, eSNP P values according to STAGE data) and their level of risk enrichments (CAD association according to GWA data sets; Figure VIII in the Data Supplement). In fact, the set of eSNPs with the strongest associations with their expression traits (ie, strongest eSNP P values according to STAGE data) were not found to be more risk enriched than the set of SNPs with weakest associations (Table XI in the Data Supplement). Second, nor was the higher risk enrichment of multitissue eQTLs lost or substantially altered in any combination of eQTL discovery FDR threshold (10%, 15%, and 20%) and major allele frequency cutoff (0.05, 0.10, and 0.15; Figure IX in the Data Supplement).
In sum, by examining eQTLs across 7 tissues, we discovered that eQTLs active across >4 tissues are important carriers of CAD/MI risk. We also identified 16 eQTLs governing the expression of 19 master regulatory genes linked to CAD. These master regulators and particularly those related to the extent of coronary atherosclerosis also affecting cholesterolester accumulation in foam cells merit further attention as putative CAD targets. 
